SoftOx Solutions AS — Share Issue/Capital Change 2024

Mar 27, 2024

SOFTX; Private placement, debt conversion and subsequent offering resolved by the extraordinary general meeting - update

SOFTX; Private placement, debt conversion and subsequent offering resolved by the extraordinary general meeting - update

As informed in Soft-Ox Solutions AS' notice release 13:45 today, the general meeting approved inter alia the private placement and the debt conversion. A minor adjustment with regard to issued shares and gross proceeds were resolved by the general meeting:

The general meeting resolved to issue 492,695,819 shares at a subscription price of NOK 0.2 per share, raising NOK 98,539,167 in gross proceed in the private placement and the debt conversion.

The share capital of the Company will following the registration of the new shares private placement and the debt conversion be NOK 10 068 473,38 divided on 503 423 609 shares with a nominal value of NOK 0.02 per share.

Oslo 27 March 2024

For any questions or interview requests, please contact:

Geir Almås, Chair of SoftOx Solutions AS

Mail: ir@soft-ox.com

Phone: Geir Almås: (+47) 977 59 071

About SoftOx Solutions AS

SoftOx Solutions AS (SoftOx) is a Medtech and pharmaceutical company listed on Euronext Growth Oslo under 'SOFTX'. SoftOx Solutions AS was founded in 2012 and is headquartered in Oslo. The SoftOx Solutions Group includes: the holding company SoftOx Solutions AS, the Malmö subsidiary, and subsidiaries SoftOx Defense Solutions AS and SoftOx Disinfection AS. SoftOx is developing a highly effective antimicrobial solution for use in biofilm, viral and antimicrobial resistant infections. The patent-protected technology is based on extensive research and development in partnership with leading Nordic research institutes.

For more information on SoftOx, visit www.soft-ox.com